Age-related macular degeneration: Clinical findings following treatment with antiangiogenic drugs

Journal of Ophthalmology

Volumn 2014, Issue , 2014, Pages

  Casaroli Marano, Ricardo ^a   Gallego Pinazo, Roberto ^b,c   Fernández Blanco, Clemencia Torrón ^c,d   Figueroa, Marta S ^e   Pina Marín, Begoña ^f   Fernández Baca Vaca, Gustavo ^g   Piñero Bustamante, Antonio ^h   Donate López, Juan ⁱ   García Arumí, José ^j   Farrés Martí, Jordi ^k  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL DOS DE MAIG   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k Bayer Healthcare   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897811349     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2014/346360     Document Type: Article

References (23)

1. Chopdar A., Chakravarthy U., Verma D., Age related macular degeneration. British Medical Journal 2003 326 7387 485 488 2-s2.0-0037374604 (Pubitemid 36269633)
2. Heier J. S., Brown D. M., Chong V., Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012 119 2537 2548
3. Cahill M. T., Banks A. D., Stinnett S. S., Toth C. A., Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology 2005 112 1 152 158 2-s2.0-11344259829 10.1016/j.ophtha.2004.06.036 (Pubitemid 40075335)
4. Spanish Eyes Epidemiological (SEE) Study Group, Prevalence of age-related macular degeneration in Spain. British Journal of Ophthalmology 2011 95 931 936
5. Owen C. G., Fletcher A. E., Donoghue M., Rudnicka A. R., How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? British Journal of Ophthalmology 2003 87 3 312 317 2-s2.0-0037340036 10.1136/bjo.87.3.312 (Pubitemid 36307906)
6. Vedula S. S., Krzystolik M. G., Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008 2 CD005139 2-s2.0-44949118622
7. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1419 1431 2-s2.0-33749445317 10.1056/NEJMoa054481 (Pubitemid 44511557)
8. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
9. Ruiz-Moreno J. M., Arias-Barquet L., Armadá-Maresca F., Boixadera-Espax A., García-Layana A., Gómez-Ulla-de- Irazazábal F., Monés-Carilla J., Piñero-Bustamante A., Suárez-de-Figueroa M., Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD). Archivos de la Sociedad Española de Oftalmología 2009 84 7 333 344 2-s2.0-77949743762
10. Pauleikhoff D., Kirchhof B., Bertram B., Holz F. G., Bartz-Schmidt U. B., Bornfeld N., Bresgen M., Heimann H., Helbig H., Hörauf H., Kampik A., Lemmen K. D., Roider J., New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy. Der Ophthalmologe 2011 108 1 85 90 2-s2.0-79955963354 10.1007/s00347-010-2326-1
11. Cohen S. Y., Mimoun G., Oubraham H., Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 2013 33 474 481
12. Hjelmqvist L., Lindberg C., Kanulf P., Dahlgren H., Johansson I., Siewert A., One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. Journal of Ophthalmology 2011 2011 8 10.1155/2011/405724 405724
13. Heimes B., Lommatzsch A., Zeimer M., Gutfleisch M., Spital G., Dietzel M., Pauleikhoff D., Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefe's Archive for Clinical and Experimental Ophthalmology 2011 249 5 639 644 2-s2.0-79955620226 10.1007/s00417-010-1524-5
14. Bloch S. B., la Cour M., Sander B., Hansen L. K. H., Fuchs J., Lund-Andersen H., Larsen M., Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmologica 2013 91 42 47 2-s2.0-80054111309 10.1111/j.1755-3768.2011. 02268.x
15. Finger R. P., Wiedemann P., Blumhagen F., Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study-a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmologica 2013 91 540 546
16. Patel P. J., Chen F. K., Rubin G. S., Tufail A., Intersession repeatability of visual acuity scores in age-related macular degeneration. Investigative Ophthalmology and Visual Science 2008 49 10 4347 4352 2-s2.0-53449093792 10.1167/iovs.08-1935
17. Gregori N. Z., Feuer W., Rosenfeld P. J., Novel method for analyzing snellen visual acuity measurements. Retina 2010 30 7 1046 1050 2-s2.0-77954759614 10.1097/IAE.0b013e3181d87e04
18. Martin D. F., Maguire M. G., Ying G.-S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine 2011 364 20 1897 1908 2-s2.0-79956218863 10.1056/NEJMoa1102673
19. Martin D. F., Maguire M. G., Fine S. L., Ying G.-S., Jaffe G. J., Grunwald J. E., Toth C., Redford M., Ferris F. L. III, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012 119 1388 1398 2-s2.0-84860591842 10.1016/j.ophtha.2012.03.053
20. Dadgostar H., Ventura A. A. C. M., Chung J. Y., Sharma S., Kaiser P. K., Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009 116 9 1740 1747 2-s2.0-69249213449 10.1016/j.ophtha.2009.05.033
21. Engelbert M., Zweifel S. A., Freund K. B., "treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009 29 10 1424 1431 2-s2.0-73349096955 10.1097/IAE.0b013e3181bfbd46
22. Monés J., A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. Ophthalmologica 2011 225 2 112 119 2-s2.0-77957727640 10.1159/000319906
23. Kaiser P. K., Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (an aos thesis). Transactions of the American Ophthalmological Society 2009 107 311 324 2-s2.0-77949352911